Cooley

Hatch-Waxman Litigation

Our lawyers are adept at resolving high-stakes ANDA disputes

Our patent litigators bring decades of experience with litigating Hatch-Waxman matters and have protected billions of dollars in sales for branded pharmaceutical companies
We regularly represent research-based pharmaceutical companies on product exclusivity issues, including defending against generic challengers in Hatch-Waxman proceedings
We understand the important strategic and regulatory issues that are unique to pharmaceutical litigation
Our lawyers advise clients in all aspects of Hatch-Waxman matters, such as reviewing Orange Book-listed patents, preparing for and litigating Paragraph IV challenges and counseling regarding antitrust considerations in settlement agreements
At Cooley, our practice seamlessly collaborates with patent prosecutors and life sciences lawyers
We’re adept at breaking down complex scientific subject matter to educate and persuade judges
Our litigators have PhDs and master’s degrees across scientific disciplines

Powerful trial and USPTO representation of leading technology and life sciences companies. – Chambers

Sanya Sukduang Partner, Washington, DC

Jonathan Davies Partner, Washington, DC

Michelle Rhyu Partner, Palo Alto

Jon Graves Partner, Reston

Adam Pivovar Partner, Washington, DC

Eamonn Gardner Partner, Colorado